Ventyx Biosciences (NASDAQ:VTYX) Cut to Hold at UBS Group

UBS Group cut shares of Ventyx Biosciences (NASDAQ:VTYX) from a strong-buy rating to a hold rating in a research note published on Thursday,Zacks.com reports.

Other equities research analysts also recently issued reports about the company. Clear Str downgraded Ventyx Biosciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday. Lifesci Capital restated a “market perform” rating and set a $14.00 price objective on shares of Ventyx Biosciences in a research report on Thursday. Wells Fargo & Company reaffirmed an “equal weight” rating and issued a $14.00 target price on shares of Ventyx Biosciences in a report on Thursday. Oppenheimer lowered shares of Ventyx Biosciences from an “outperform” rating to a “market perform” rating in a research note on Thursday. Finally, HC Wainwright downgraded shares of Ventyx Biosciences from a “buy” rating to a “neutral” rating and set a $14.00 price objective for the company. in a research report on Thursday. Eight analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Reduce” and a consensus price target of $14.86.

Ventyx Biosciences Stock Performance

Shares of VTYX opened at $13.81 on Thursday. Ventyx Biosciences has a fifty-two week low of $0.78 and a fifty-two week high of $25.00. The firm has a 50-day simple moving average of $9.27 and a 200-day simple moving average of $5.30. The company has a market capitalization of $985.48 million, a price-to-earnings ratio of -9.21 and a beta of 1.23.

Ventyx Biosciences (NASDAQ:VTYX) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.13. Equities research analysts forecast that Ventyx Biosciences will post -2.09 EPS for the current year.

Insider Buying and Selling

In other news, insider John Nuss sold 12,675 shares of Ventyx Biosciences stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of $7.72, for a total transaction of $97,851.00. Following the completion of the sale, the insider directly owned 489,481 shares in the company, valued at approximately $3,778,793.32. This trade represents a 2.52% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Raju Mohan sold 47,345 shares of the business’s stock in a transaction that occurred on Thursday, December 18th. The stock was sold at an average price of $7.72, for a total value of $365,503.40. Following the sale, the chief executive officer directly owned 2,372,863 shares in the company, valued at $18,318,502.36. This trade represents a 1.96% decrease in their position. The SEC filing for this sale provides additional information. 14.49% of the stock is currently owned by company insiders.

Institutional Trading of Ventyx Biosciences

Several large investors have recently bought and sold shares of the company. Hudson Bay Capital Management LP purchased a new position in shares of Ventyx Biosciences in the second quarter valued at $34,000. Pallas Capital Advisors LLC purchased a new position in Ventyx Biosciences during the 2nd quarter valued at about $38,000. Engineers Gate Manager LP purchased a new stake in shares of Ventyx Biosciences in the second quarter valued at about $42,000. Persistent Asset Partners Ltd acquired a new stake in shares of Ventyx Biosciences in the third quarter valued at approximately $51,000. Finally, Jump Financial LLC purchased a new position in shares of Ventyx Biosciences during the 2nd quarter worth approximately $53,000. Institutional investors and hedge funds own 97.88% of the company’s stock.

Key Ventyx Biosciences News

Here are the key news stories impacting Ventyx Biosciences this week:

• Positive Sentiment: Lilly confirms definitive agreement to acquire Ventyx for $14.00 per share (≈$1.2B total), providing a clear cash exit and a floor under the stock while closing risk and timing remain uncertainties. Lilly to acquire Ventyx Biosciences
• Positive Sentiment: UBS begins coverage with a Buy rating and $20.00 price target, implying material upside from the current market level and signaling confidence in Ventyx’s assets/strategic value to acquirers. UBS coverage reported
• Neutral Sentiment: Wells Fargo reaffirmed an “equal weight” rating with a $14.00 price target — effectively in line with the acquisition price and suggesting limited near-term upside beyond the deal consideration. Wells Fargo note
• Neutral Sentiment: Lifesci Capital and Lifesci-related coverage moved to “market perform”/”hold” around the deal price, indicating analysts are treating the announced transaction as the primary valuation anchor. Lifesci/Lifesci Capital coverage
• Negative Sentiment: Several sell-side firms (Oppenheimer, Canaccord Genuity, Clear Street) issued downgrades or cut enthusiasm for VTYX after the deal — moves that can add selling pressure on any remaining float and reflect concerns about upside beyond the $14 offer. Oppenheimer downgrade Canaccord downgrade
• Negative Sentiment: Multiple law firms have launched investigations and shareholder alerts alleging possible unfair process or inadequate price in the Lilly deal; such litigation can delay closing, raise transaction costs, and add uncertainty around final shareholder recoveries. Kahn Swick & Foti investigation Edelson Lechtzin investigation

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome.